Medical ProgressAdvances in Anti-GD2 Immunotherapy for Treatment of High-risk NeuroblastomaVoeller, Julie MD*; Sondel, Paul M. MD, PhD*,†Author Information *Department of Pediatrics, Division of Hematology, Oncology and Bone Marrow Transplant †Departments of Human Oncology and Genetics and Carbone Cancer Center, University of Wisconsin, Madison, WI Supported NIH Grants CA032685, CA87025, CA166105, CA197078, and GM067386, The University of Wisconsin ICTR Grant 1TL1RR025013-01, The University of Wisconsin Carbone Cancer Center Core Grant, P30CA014520, The University of Wisconsin UW2020 grant, The Midwest Athletes for Childhood Cancer Fund, The Hyundai Hope on Wheels Foundation and The St. Baldrick’s-Stand Up To Cancer Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. The authors declare no conflict of interest. Reprints: Paul M. Sondel, MD, PhD, 4159 WIMR Building, 1111 Highland Avenue, Madison, WI 53705 (e-mail: [email protected]). Journal of Pediatric Hematology/Oncology: April 2019 - Volume 41 - Issue 3 - p 163-169 doi: 10.1097/MPH.0000000000001369 Buy Metrics Abstract Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective antidisialoganglioside (anti-GD2) monoclonal antibody (mAb) have been studied for several decades now, but have only recently been incorporated into standard of care treatment for patients with high-risk NBL with clear benefit. Here we review a brief history of anti-GD2-based immunotherapy, current areas of neuroblastoma research targeting GD2, and potential diagnostic and therapeutic uses targeting GD2. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.